StageZero Life Sciences Ltd.
SZLSF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $3,795 | $5,068 | $4,152 | $139 |
| % Growth | -25.1% | 22.1% | 2,893.3% | – |
| Cost of Goods Sold | $4,199 | $3,891 | $3,456 | $1,100 |
| Gross Profit | -$404 | $1,177 | $696 | -$961 |
| % Margin | -10.6% | 23.2% | 16.8% | -692.8% |
| R&D Expenses | $352 | $775 | $219 | $0 |
| G&A Expenses | $5,906 | $6,979 | $4,021 | $4,179 |
| SG&A Expenses | $6,652 | $8,222 | $4,213 | $4,179 |
| Sales & Mktg Exp. | $746 | $1,244 | $14 | $0 |
| Other Operating Expenses | $339 | $311 | $0 | $0 |
| Operating Expenses | $7,343 | $9,308 | $4,432 | $4,179 |
| Operating Income | -$7,747 | -$7,963 | -$3,737 | -$5,113 |
| % Margin | -204.1% | -157.1% | -90% | -3,686.2% |
| Other Income/Exp. Net | -$3,669 | $479 | -$3,127 | $1,407 |
| Pre-Tax Income | -$11,415 | -$7,484 | -$6,864 | -$3,482 |
| Tax Expense | $0 | $0 | $0 | $830 |
| Net Income | -$11,415 | -$7,484 | -$6,864 | -$3,482 |
| % Margin | -300.8% | -147.7% | -165.3% | -2,510.2% |
| EPS | -0.11 | -0.1 | -0.15 | -0.16 |
| % Growth | -10% | 33.3% | 6.3% | – |
| EPS Diluted | -0.11 | -0.1 | -0.15 | -0.16 |
| Weighted Avg Shares Out | 99,426 | 70,716 | 44,821 | 26,499 |
| Weighted Avg Shares Out Dil | 99,426 | 70,716 | 44,821 | 26,499 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $35 | $0 |
| Interest Expense | $284 | $200 | $699 | $803 |
| Depreciation & Amortization | $420 | $308 | $268 | $305 |
| EBITDA | -$10,270 | -$5,686 | -$6,259 | -$2,436 |
| % Margin | -270.6% | -112.2% | -150.7% | -1,756.2% |